Provided by Tiger Trade Technology Pte. Ltd.

Invesco S&P SmallCap Health Care ETF

54.93
+0.37000.68%
Volume:13.72K
Turnover:752.05K
Market Cap:185.11M
PE:- -
High:55.09
Open:54.44
Low:54.44
Close:54.56
52wk High:56.45
52wk Low:39.08
Shares:3.37M
Float Shares:3.37M
Volume Ratio:1.07
T/O Rate:0.41%
Dividend:0.00
Dividend Rate:0.01%
ROE:--
ROA:--
PB:--
PE(LYR):- -

Loading ...

Brightspring Health Svcs is Maintained at Overweight by Morgan Stanley

Dow Jones
·
Jul 14

Analysts Have Conflicting Sentiments on These Healthcare Companies: Alnylam Pharma (ALNY), Madrigal Pharmaceuticals (MDGL) and Krystal Biotech (KRYS)

TIPRANKS
·
Jul 14

Caris Life Sciences expands prostate cancer offering with PTEN IHC testing

TIPRANKS
·
Jul 14

Krystal Biotech Inc : Bofa Global Research Raises Price Objective to $396 from $364

THOMSON REUTERS
·
Jul 14

BrightSpring Health price target raised to $80 from $60 at KeyBanc

TIPRANKS
·
Jul 14

Molina Healthcare Inc : TD Cowen Raises Target Price to $230 from $163

THOMSON REUTERS
·
Jul 14

Analysts Offer Insights on Healthcare Companies: Arrowhead Pharmaceuticals (ARWR) and BrightSpring Health Services, Inc. (BTSG)

TIPRANKS
·
Jul 14

Brightspring Health Services Inc : Keybanc Raises Target Price to $80 from $60

THOMSON REUTERS
·
Jul 14

BioArctic’s Partner Eisai Wins FDA Nod for At-Home Leqembi Injection in Early Alzheimer’s

TIPRANKS
·
Jul 14

Analysts Conflicted on These Healthcare Names: Alkermes (ALKS), TransMedics Group (TMDX) and Praxis Precision Medicines (PRAX)

TIPRANKS
·
Jul 14

Molina Health is Maintained at Equal-weight by Wells Fargo

Dow Jones
·
Jul 13

Analysts Offer Insights on Healthcare Companies: Genmab (GMAB), Krystal Biotech (KRYS) and Denali Therapeutics (DNLI)

TIPRANKS
·
Jul 13

Alkermes Plc : TD Cowen Raises Target Price to $57 from $50

THOMSON REUTERS
·
Jul 13

Brightspring Health Svcs Initiated at Buy by Guggenheim

Dow Jones
·
Jul 13

Analysts’ Top Healthcare Picks: Molina Healthcare (MOH), Adicet Bio (ACET)

TIPRANKS
·
Jul 13

Alkermes Price Target Announced at $60.00/share by JP Morgan

Dow Jones
·
Jul 13

Alkermes Says Alixorexton Sustains Wakefulness Gains in Nine-month Narcolepsy Extension Study Interim Analysis

Reuters
·
Jul 13

Alkermes - Alixorexton Generally Well Tolerated at All Doses Tested

THOMSON REUTERS
·
Jul 13

Alkermes - Alixorexton Shows Sustained Improvement on Mwt and ESS at Week 24, Nine Months After First Dose

THOMSON REUTERS
·
Jul 13

Alkermes’ Alixorexton Demonstrated Sustained Improvement in Wakefulness in Adults with Narcolepsy Type 1 and Type 2 in Long-term Extension Study Interim Analysis

THOMSON REUTERS
·
Jul 13